HIND Stock Rallies 70% Pre-Market Today – Find Out Why

In a preclinical model of anterior uveitis, the twice-daily application of VT-1908 eyedrops significantly reduced the uveitis score, Vyome said.
Rising stock market chart on a trading board background.
Rising stock market chart on a trading board background. | Image source: Yuichiro Chino on Getty Images
Profile Image
Anan Ashraf·Stocktwits
Updated Sep 17, 2025 | 8:49 AM GMT-04
Share this article

Vyome Holdings, Inc. (HIND) announced on Wednesday that its VT-1908 eyedrop has been shown to significantly reduce uveitis scores in preclinical models. Shares of the company rallied by over 60% in pre-market trading on Wednesday.

Uveitis is the inflammation of a part of the eye and is implicated in approximately 30,000 new cases of legal blindness annually in the United States alone, according to Vyome.  

In a preclinical model of anterior uveitis, the twice-daily application of VT-1908 eyedrops significantly reduced the uveitis score, and the efficacy of the drug was found to be similar to a clinically used steroid, the company stated.

Get updates to this developing story directly on Stocktwits.

Subscribe to Trends with Friends
All Newsletters
For serious investors with a serious sense of humor.
Read about our editorial guidelines and ethics policy